|
The
Hoodia in EphedraP57™ contains the only form of Hoodia
that has been clinically tested in America. This study proved
that the median weight loss over 28 days is 10 pounds with
an average decrease in body fat of 3.3%. This weight loss
is considered a healthy weight loss that can stay off. The
participants interviewed stated that their caloric intake
decreased to less than half in only a few days of being on
the Hoodia Gordonii used in EphedraP57™.
The
participants in the study were first categorized as being
AT LEAST overweight. Overweight is defined as being AT LEAST
25 pounds over their body’s natural weight zone. 30-39
is considered obesity and 40 or greater is considered severely
obese. The requirements of each participant where as follows:
-
Each participant was required to eat a balanced breakfast
with a multivitamin supplement in the AM.
- Each
participant was required to take 2 Hoodia Gordonii Hoodia
Chews capsules daily. The first capsule, 1-hour prior to
lunchtime with 8 ounces of water and the second capsule
1 hour prior to dinner with a minimum of 8 ounces of water.
- Each
participant was required to have their weight recorded on
days 0, 7, 14, and 28.
The
product has not been shown to interact with any other medications
being taken. No major side effects have been reported. No
other weight loss products were taken during the 28-day study.
Each participant was instructed not to alter his or her dietary
habits. All participants utilized One (1) Detecto scale. Each
weight was checked by Dr. Goldfarb to ensure quality control
and accuracy. All weights were entered at the time of weigh
in. Compliance of the participants was excellent. All patients
did not alter their dietary habits and/or their daily activity
during the 28-day study.
CONCLUSION:
This
study proved that the median weight loss over 28 days is 10
pounds with an average decrease in body fat of 3.3%.
No
side effects such as nausea, vomiting, diarrhea, jitteriness,
or change in sleep habits were reported.
Author
contributions Study conception and design: Richard
M. Goldfarb, M.D. FACS Analysis and interpretation of data:
Richard M, Goldfarb, M.D. FACS Critical revision: David J.
Miller, D.O. FAAP Supervision: David J. Miller, D.O. FAAP
|
